Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Brainstorm Cell Therapeutics Presentations At Neuromuscular Drug Development Summit is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
NEW YORK, April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics ... and development, with a proven track record of leading successful clinical trials and fostering innovation in drug ... Read More
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time BrainStorm Cell Therapeutics Inc ... MS Society (NMSS). This press release contains "forward-looking ... Read More
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ ... Forward-Looking Statements This press release contains "forward-looking statements" that are ... Read More
5 Mid-Stage ALS Drugs to Watch
As the Phase III amyotrophic lateral sclerosis pipeline thins out, the ALS community is placing its hopes on earlier-stage trials sponsored by Denali Therapeutics, PTC Therapeutics and more. Read More
Brainstorm Cell Therapeutics Inc. (BCLI)
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that it received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on the ... Read More
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm ... stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug ... Read More
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics ... press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus